share_log

Modular Medical Announces Proposed Public Offering

Modular Medical Announces Proposed Public Offering

模块化医疗宣布拟议的公开募股
Accesswire ·  02/15 16:15

SAN DIEGO, CA / ACCESSWIRE / February 15, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical"), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced that it has commenced an underwritten public offering (the "offering") of shares of its common stock (or pre-funded warrants to purchase shares of its common stock in lieu thereof). Modular Medical also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock (or pre-funded warrants). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Modular Medical.

加利福尼亚州圣地亚哥/ACCESSWIRE/2024年2月15日/Modular Medical, Inc.(纳斯达克股票代码:MODD)(“模块化医疗”)是一家处于开发阶段的胰岛素输送技术公司,旨在推出下一代易于使用且价格合理的胰岛素泵技术,今天宣布,它已开始承销其普通股(或预先筹资的认股权证),以代替普通股的公开发行(“发行”))。Modular Medical还打算授予承销商30天的期权,允许其额外购买其普通股(或预先注资的认股权证)总数的15%。本次发行受市场和其他条件的约束,无法保证发行是否或何时完成,也无法保证发行的实际规模或条款。拟议发行中出售的所有普通股和预先注资的认股权证将由Modular Medical出售。

Titan Partners Group, a division of American Capital Partners, is acting as sole book-running manager for the proposed offering.

美国资本合伙人旗下的泰坦合伙人集团担任拟议发行的唯一账面经理。

The offering is being made pursuant to an effective "shelf" registration statement on Form S-3 (File No. 333-264193) previously filed with the Securities and Exchange Commission (the "SEC") on April 8, 2022, as amended on April 15, 2022, and declared effective by the SEC on April 19, 2022. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC. Electronic copies of the preliminary prospectus and, when available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained by visiting the SEC's website at www.sec.gov or by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, New York 10007, by phone at (929) 833-1246 or by email at info@titanpartnersgrp.com.

此次发行是根据先前于2022年4月8日向美国证券交易委员会(“SEC”)提交的S-3表格(文件编号333-264193)上的有效 “货架” 注册声明进行的,该声明于2022年4月15日修订,美国证券交易委员会于2022年4月19日宣布生效。证券只能通过招股说明书发行。初步的招股说明书补充文件以及与发行条款有关和描述的随附招股说明书已向美国证券交易委员会提交。初步招股说明书的电子副本以及最终招股说明书补充文件以及与本次发行相关的随附招股说明书的副本(如果有)可通过访问美国证券交易委员会的网站www.sec.gov或联系美国资本合伙人有限责任公司下属的泰坦合伙人集团有限责任公司获取,世界贸易中心4号,29第四 Floor,纽约,纽约 10007,致电 (929) 833-1246 或发送电子邮件至 info@titanpartnersgrp.com。

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

本新闻稿不构成出售要约或招揽购买这些证券的要约,在根据任何此类州或司法管辖区的证券法进行注册或获得资格之前,在任何州或其他司法管辖区内,此类要约、招标或出售属于非法行为,也不得出售这些证券。

About Modular Medical

关于模块化医疗

Modular Medical, Inc. (NASDAQ: MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."

Modular Medical, Inc.(纳斯达克股票代码:MODD)是一家处于开发阶段的医疗器械公司,打算推出下一代胰岛素输送技术。该公司利用其专利技术,力求消除复杂性和功效之间的权衡,从而使高质量的胰岛素输送既经济实惠又易于学习。我们的使命是改善糖尿病患者获得最高标准血糖控制的机会,使其不仅限于 “超级使用者”,并提供 “为我们其他人提供糖尿病护理”。

Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at

Modular Medical由经验丰富的医疗器械专业人士和微流控工程师保罗·迪佩尔纳创立。在创立Modular Medical之前,Diperna先生是Tandem Diabetes的创始人(2005年),他发明并设计了其t: slim胰岛素泵。更多信息可在以下网址获得

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified through the use of words such as may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including whether or when the offering may be completed. These factors include, but are not limited to, whether Modular Medical can successfully develop its proprietary technologies, whether the market will accept Modular Medical's products and services, whether the Company will be issued additional patents for its proprietary technology, Modular Medical's ability to obtain regulatory clearance for its MODD1 product, anticipated consumer demand for its products, whether Modular Medical can successfully manufacture its products at high volumes, general economic, industry or political conditions in the United States or internationally as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.

本新闻稿包含根据1995年《私人证券诉讼改革法》的安全港条款做出的前瞻性陈述。前瞻性陈述可以通过使用诸如 “可能”、“可能”、“将”、“打算”、“应该”、“可以”、“将”、“继续”、“期望”、“相信”、“预期”、“估计”、“预测”、“潜在”、“计划”、“寻求” 等词语以及这些术语的类似表述和变体或否定词来识别或其他类似的术语。此类前瞻性陈述受风险、趋势和不确定性的影响,这些风险、趋势和不确定性可能导致实际业绩与本新闻稿中包含的前瞻性陈述存在重大差异,包括发行是否或何时完成。这些因素包括但不限于:模块化医疗能否成功开发其专有技术,市场是否会接受模块化医疗的产品和服务,公司的专有技术是否会获得更多专利,模块化医疗获得其 MODD1 产品的监管许可的能力,消费者对其产品的预期需求,模块化医疗能否在美国成功地在总体经济、行业或政治条件下大批量生产其产品,或国际上以及Modular Medical向美国证券交易委员会提交的文件(包括其10-K表年度报告)中描述的其他风险因素和业务考虑因素。本新闻稿中的任何前瞻性陈述都应根据这些重要的风险因素进行评估。此外,本新闻稿中包含的任何前瞻性陈述仅代表Modular Medical截至其发布之日的观点,不应以此作为其后任何日期的观点。除非法律要求,否则Modular Medical不承担更新这些前瞻性陈述的义务。

Contact Information
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com

联系信息
Jeb Besser
首席执行官
模块化医疗有限公司
+1 (617) 399-1741
IR@modular-medical.com

SOURCE: Modular Medical, Inc.

资料来源:模块化医疗公司


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发